{"id":11212,"date":"2026-09-22T17:02:57","date_gmt":"2026-09-22T17:02:57","guid":{"rendered":"https:\/\/stoxpo.com\/?p=11212"},"modified":"2026-09-22T17:02:57","modified_gmt":"2026-09-22T17:02:57","slug":"viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2026\/09\/22\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\/","title":{"rendered":"Viking Therapeutics Reports Positive VK2735 Maintenance Data as Obesity Drug Advances"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">GLP-1\/GIP candidate delivers 22% placebo-adjusted weight loss while less-frequent dosing shows potential for maintaining results<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Viking Therapeutics (VKTX) announced positive topline results Tuesday from a maintenance study evaluating its experimental obesity drug VK2735, highlighting the potential for multiple dosing schedules designed to help patients maintain weight loss.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Phase 1 study evaluated VK2735, a dual GLP-1\/GIP receptor agonist, across weekly, every-other-week and monthly maintenance regimens following an initial treatment period.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Patients receiving a 17.5 mg weekly dose achieved approximately 22% placebo-adjusted weight loss at Week 33, with no plateau in weight reduction observed. Importantly, participants transitioned to every-other-week dosing maintained up to 97% of their prior weight loss over three months.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The findings suggest VK2735 could potentially offer patients greater flexibility after reaching their weight-loss goals, including less frequent injections. Such dosing options could become important in the competitive obesity-treatment market, where long-term adherence remains a major consideration.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">VK2735 is already Viking\u2019s most advanced clinical candidate. The company\u2019s Phase 3 VANQUISH-1 and VANQUISH-2 trials evaluating the injectable formulation in obesity are fully enrolled and progressing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Viking is also developing an oral version of VK2735, with Phase 3 development expected to broaden the company\u2019s approach to the rapidly expanding obesity market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The latest maintenance data further strengthen Viking\u2019s case that VK2735 could eventually provide patients with multiple options for both achieving and sustaining significant weight loss.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>GLP-1\/GIP candidate delivers 22% placebo-adjusted weight loss while less-frequent dosing shows potential for maintaining results Viking Therapeutics (VKTX) announced positive topline results Tuesday from a maintenance study evaluating its experimental obesity drug VK2735, highlighting the potential for multiple dosing schedules designed to help patients maintain weight loss. The Phase 1 study evaluated VK2735, a dual [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1142,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[],"footnotes":""},"categories":[308,360],"tags":[421,416,418,417,793],"coauthors":[453],"class_list":["post-11212","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","category-mid-cap","tag-growth","tag-movers","tag-news","tag-stock-market","tag-vktx"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Viking Therapeutics Reports Positive VK2735 Maintenance Data as Obesity Drug Advances - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2026\/09\/22\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viking Therapeutics Reports Positive VK2735 Maintenance Data as Obesity Drug Advances - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"GLP-1\/GIP candidate delivers 22% placebo-adjusted weight loss while less-frequent dosing shows potential for maintaining results Viking Therapeutics (VKTX) announced positive topline results Tuesday from a maintenance study evaluating its experimental obesity drug VK2735, highlighting the potential for multiple dosing schedules designed to help patients maintain weight loss. The Phase 1 study evaluated VK2735, a dual [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2026\/09\/22\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-22T17:02:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-tima-miroshnichenko-9574530-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Liliana Vida\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Liliana Vida\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/09\\\/22\\\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/09\\\/22\\\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\\\/\"},\"author\":{\"name\":\"Liliana Vida\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\"},\"headline\":\"Viking Therapeutics Reports Positive VK2735 Maintenance Data as Obesity Drug Advances\",\"datePublished\":\"2026-09-22T17:02:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/09\\\/22\\\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\\\/\"},\"wordCount\":234,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/09\\\/22\\\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-tima-miroshnichenko-9574530-scaled.jpg\",\"keywords\":[\"Growth\",\"Movers\",\"News\",\"Stock Market\",\"VKTX\"],\"articleSection\":[\"Biotechnology\",\"Mid-Cap\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/09\\\/22\\\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/09\\\/22\\\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\\\/\",\"name\":\"Viking Therapeutics Reports Positive VK2735 Maintenance Data as Obesity Drug Advances - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/09\\\/22\\\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/09\\\/22\\\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-tima-miroshnichenko-9574530-scaled.jpg\",\"datePublished\":\"2026-09-22T17:02:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/09\\\/22\\\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/09\\\/22\\\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/09\\\/22\\\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-tima-miroshnichenko-9574530-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-tima-miroshnichenko-9574530-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/09\\\/22\\\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viking Therapeutics Reports Positive VK2735 Maintenance Data as Obesity Drug Advances\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\",\"name\":\"Liliana Vida\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"caption\":\"Liliana Vida\"},\"description\":\"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/stoxpo-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Viking Therapeutics Reports Positive VK2735 Maintenance Data as Obesity Drug Advances - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2026\/09\/22\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\/","og_locale":"en_US","og_type":"article","og_title":"Viking Therapeutics Reports Positive VK2735 Maintenance Data as Obesity Drug Advances - Stoxpo","og_description":"GLP-1\/GIP candidate delivers 22% placebo-adjusted weight loss while less-frequent dosing shows potential for maintaining results Viking Therapeutics (VKTX) announced positive topline results Tuesday from a maintenance study evaluating its experimental obesity drug VK2735, highlighting the potential for multiple dosing schedules designed to help patients maintain weight loss. The Phase 1 study evaluated VK2735, a dual [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2026\/09\/22\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\/","og_site_name":"Stoxpo","article_published_time":"2026-09-22T17:02:57+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-tima-miroshnichenko-9574530-scaled.jpg","type":"image\/jpeg"}],"author":"Liliana Vida","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Liliana Vida","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2026\/09\/22\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/09\/22\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\/"},"author":{"name":"Liliana Vida","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1"},"headline":"Viking Therapeutics Reports Positive VK2735 Maintenance Data as Obesity Drug Advances","datePublished":"2026-09-22T17:02:57+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/09\/22\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\/"},"wordCount":234,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/09\/22\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-tima-miroshnichenko-9574530-scaled.jpg","keywords":["Growth","Movers","News","Stock Market","VKTX"],"articleSection":["Biotechnology","Mid-Cap"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2026\/09\/22\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\/","url":"https:\/\/stoxpo.com\/index.php\/2026\/09\/22\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\/","name":"Viking Therapeutics Reports Positive VK2735 Maintenance Data as Obesity Drug Advances - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/09\/22\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/09\/22\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-tima-miroshnichenko-9574530-scaled.jpg","datePublished":"2026-09-22T17:02:57+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/09\/22\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2026\/09\/22\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2026\/09\/22\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-tima-miroshnichenko-9574530-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-tima-miroshnichenko-9574530-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2026\/09\/22\/viking-therapeutics-reports-positive-vk2735-maintenance-data-as-obesity-drug-advances\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"Viking Therapeutics Reports Positive VK2735 Maintenance Data as Obesity Drug Advances"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1","name":"Liliana Vida","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6","url":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","caption":"Liliana Vida"},"description":"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/stoxpo-com\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/11212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=11212"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/11212\/revisions"}],"predecessor-version":[{"id":11213,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/11212\/revisions\/11213"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1142"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=11212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=11212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=11212"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=11212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}